THYMALIN [THYMUS EXTRACT]

Formulation

Thymalin is a polypeptide medicine containing extract of cattle thymus in proportion 10 mg per bottle.

Pharmacological effect

This medication restores the immune reactivity (by regulating the ratio and interaction of T and B lymphocytes and the subpopulations thereof, stimulating the cellular immunity and enhancing the phagocytosis), prevents the suppression of regeneration and hematogenesis and enhances cell metabolism.

Application and dosage

Dilute the content of one bottle in 1-2 ml of isotonic solution of sodium chloride before injection. The medication is applied intramuscularly daily: dosage for adults is 5-20 mg (a course of 30-100 mg), for infants under 1 year - 1 mg; for 1-3 year olds - 1.5-2 mg; for 4-6 year olds - 2-3 mg; for 7-14 year olds - 3-5 mg over 3-10 days. If necessary, the treatments can be repeated after 1-6 month. As a prevention, the medication is applied intramuscularly daily, adults 5-10 mg, children 1-5 mg over 3-5 days.

Compatibility

Thymalin is highly compatible with other medicines.

Thymalin is a polypeptide medicine containing extract of cattle thymus in proportion 10 mg per bottle.

This medication induces proliferation and differentiation of T lymphocytes (Thymus-dependent lymphocytes) precursors into mature T cells, stabilises the T lymphocyte subpopulations ratio, regulates the T and B lymphocyte interaction and activates phagocytic function in neutrophils, microphages, monocytes and NK cells (Natural-killer cells).

Thymalin was developed in 1974 from calf thymus. In 1992, it was registered as an immunomodulator.

Indication

Thymalin is recommended for adults and children from six months of age:

  • as a part of complex therapy of bacterial and chlamydia infections (in gynaecology and urology);
  • as a part of complex therapy of acute and chronic inflammatory infections that are accompanied by impairment of cellular immunity (treatment of osteomyelitis, prostatitis, etc.);
  • for preventing the suppression of immunity, hematogenesis and regeneration processes in the post-traumatic and post-operative period (treatment of full-thickness burns and frostbites);
  • during radiotherapy or chemotherapy treatment and while taking massive doses of antibiotics (in oncology);
  • for prevention and complex treatment of viral infections, including URI (upper respiratory infection) and influenza (treating children with frequent and long-term illnesses).

Thymalin is a natural physiological immunostimulant. The medication stabilises the immune response and regulates the T and B cell ratio. Thymalin has a broader application scope. It can be used in case of immunosuppression of any origin and is compatible with antiviral medication. Thymalin is suitable for children aged 6 months or older. The fact that children as young as 6 months of age are allowed to take this medicine proves its safety. When applied in accordance with dosage regimen, the medication does not cause side reactions and is well tolerated. Thymalin produces a mild, natural physiological immunological effect without disturbing (over-stimulating) the immune response. The regeneration enhancement (the second component of the action of Thymalin) provides for better healing time with no side effects. The reliability of Thymalin is confirmed by more than 40 years of experience in clinical use.

The results of the clinical use of Thymalin in paediatrics

The clinical observation confirms the safety of thymus mediciations use in children, including infants.

  • Thymus mediciations can be the drugs of choice, when included in the complex therapy of severe diseases of viral and viral-bacterial etiology in children of any age.
  • Thymus mediciations can be used as monotherapy in children with frequent ARVI (acute respiratory viral infections), especially in children with a history of thymomegaly (thymic hyperplasia).
  • Long-term results (up to 17 years of observation) of treatment with thymus mediciations indicate their protective effect. None of the children during the follow-up period (for 17 years) had repeated pneumonia, relapses of osteomyelitis, sepsis, candidiasis of the skin and mucous membranes, candidal meningitis or infective endocarditis.

Thymalin in oncology

The use of Thymalin can significantly reduce the frequency of metastasis of malignant tumors by 2.3 times

Using Thymalin to treat children with chronic gastroduodenitis

Sample: 34 patients with chronic gastroduodenitis aged 10-16 years. Thymalin treatment significantly reduced the number of hemolyzed cells. The use of Thymalin in treating chronic gastroduodenitis helps alleviate clinical manifestations of the disease and inhibits the processes of excessive lipid peroxidation.

The impact of Thymalin on the cytokine dynamics in children with infective endocarditis

Thymalin treatment provides a higher stability of the cytokine level.

The impact of Thymalin on the haemostatic system in patients with urgent and complicated acute appendicitis

The use of Thymalin in combination with standard therapy leads to the stabilisation of blood clotting and fibrinolysis and eliminates the manifestations of DIC (disseminated intravascular coagulation)

Using Thymalin to treat children with CLD (chronic lung disease)

Sample: 28 children with CLD (16 with bronchiectasis and 12 with chronic bronchitis deformans) The use of Thymalin significantly enhances the CLD treatment and stabilises cellular and humoral immunity.

The use of Thymalin helps reduce the disease duration, restore the immune system and prevent or significantly reduce the likelihood of developing complications.

  1. Kuznik et al (1981) Effect of thymalin on blood coagulation and fibrinolysis https://www.ncbi.nlm.nih.gov/pubmed/7286199
  2. Dekster et al (1984) Clinico-immunologic changes in patients with cervical cancer after treatment with thymalin https://www.ncbi.nlm.nih.gov/pubmed/6608824
  3. Bakhidze (1985) Use of thymalin in the complex treatment of patients with cancer of the uterus https://www.ncbi.nlm.nih.gov/pubmed/3839953
  4. Kiselev et al (1985) Effect of thymalin on the function of the blood kallikrein-kinin system in thymectomized rats https://www.ncbi.nlm.nih.gov/pubmed/2990599
  5. Pastorova et al (1989) Comparative study of the effect of the thymus preparations thymoptin and thymalin on fibrin-monomer polymerization https://www.ncbi.nlm.nih.gov/pubmed/2744143
  6. Khlystova et al (1989) The dynamics of thymalin localization in human thymus cells in embryogenesis https://www.ncbi.nlm.nih.gov/pubmed/2699438
  7. Kogosova et al (1990) Effectiveness of administration of thymalin in the complex treatment of pulmonary tuberculosis https://www.ncbi.nlm.nih.gov/pubmed/2080155
  8. E Bakhidze, J Bokhman (1990) Application of thymic factor "Thymalin" in complex treatment of endometrial cancer patients https://www.ncbi.nlm.nih.gov/pubmed/2245808
  9. V Iangolenko (1991) The effect of combined therapy with the use of thymalin and piracetam on the level of middle-molecule peptides in the blood and on the lipid peroxidation activity in patients with diffuse toxic goiter https://www.ncbi.nlm.nih.gov/pubmed/1725225
  10. Chukhlovina et al(1994) The immunomodulating and metabolic actions of thymalin in an experimental herpetic infection https://www.ncbi.nlm.nih.gov/pubmed/7992545
  11. I Kazantseva, R Bikbulatov (1994) Thymalin in the treatment of herpetic stomatitis in children https://www.ncbi.nlm.nih.gov/pubmed/8191521
  12. V Morozov, V Khavinson (1997) Natural and synthetic thymic peptides as therapeutics for immune dysfunction https://www.ncbi.nlm.nih.gov/pubmed/9637345
  13. M Musaev (2001) Comparative study of the effects of thymalin and vitamin E on certain indices for local pulmonary protection in rheumatoid arthritis https://www.ncbi.nlm.nih.gov/pubmed/11692697
  14. Khlystova et al (2002) Age-related changes of thymalin content in human epidermis https://www.ncbi.nlm.nih.gov/pubmed/12447484
  15. V Khavinson, V Morozov (2002) Geroprotective effect of thymalin and epithalamin https://www.ncbi.nlm.nih.gov/pubmed/12577695
  16. V Khavinson, V Morozov (2003) Peptides of pineal gland and thymus prolong human life https://www.ncbi.nlm.nih.gov/pubmed/14523363
  17. Kuznetsova et al (2013) Comparative study of immunomodulatory activity of peptides, tinrostim and thymalin https://www.ncbi.nlm.nih.gov/pubmed/24734422
  18. Zhukova et al (2018) Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo https://www.ncbi.nlm.nih.gov/pubmed/29797130


Type: Unknown Type




CUSTOMERS WHO BOUGHT THIS PRODUCT ALSO BOUGHT